- Home
- KOD
as 05-30-2025 4:00pm EST
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 259.6M | IPO Year: | 2018 |
| Target Price: | $9.00 | AVG Volume (30 days): | 440.1K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.92 - $11.60 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kodiak Sciences Inc News
KOD Breaking Stock News: Dive into KOD Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
Zacks
17 days ago
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
PR Newswire
17 days ago
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
PR Newswire
a month ago
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
Simply Wall St.
a month ago
April 2025's Promising Penny Stocks
Zacks
2 months ago
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)
Zacks
2 months ago
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
PR Newswire
2 months ago
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Compare KOD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KOD Kodiak Sciences Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.